Adial Pharmaceuticals Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Adial Pharmaceuticals stock.
View analyst ratings for Adial Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Adial Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adial Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Adial Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,240,000 shares, an increase of 102.9% from the June 15th total of 611,000 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 7.9% of the company's stock are sold short.
View Adial Pharmaceuticals' Short Interest.

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Adial Pharmaceuticals.

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADIL shares have increased by 74.8% and is now trading at $2.36.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued 1 year price targets for Adial Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts' price targets for Adial Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Adial Pharmaceuticals include Decibel Therapeutics (DBTX), Corbus Pharmaceuticals (CRBP), Strongbridge Biopharma (SBBP), Mereo BioPharma Group (MREO), Satsuma Pharmaceuticals (STSA), Flora Growth (FLGC), IMV (IMV), Anebulo Pharmaceuticals (ANEB), PhaseBio Pharmaceuticals (PHAS), Milestone Pharmaceuticals (MIST), Synlogic (SYBX), vTv Therapeutics (VTVT), Equillium (EQ), Heat Biologics (HTBX) and Novan (NOVN).
View all of ADIL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu Biopharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Adial Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Golden Green Inc. (0.13%). Company insiders that own Adial Pharmaceuticals stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends for Adial Pharmaceuticals.

ADIL stock was acquired by a variety of institutional investors in the last quarter, including Golden Green Inc.. Company insiders that have bought Adial Pharmaceuticals stock in the last two years include James W Jr Newman, and William B Stilley III.
View insider buying and selling activity for Adial Pharmaceuticals or or view top insider-buying stocks.

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADIL stock can currently be purchased for approximately $2.36.

Adial Pharmaceuticals has a market capitalization of $43.44 million.

Adial Pharmaceuticals employs 147,000 workers across the globe.

The official website for Adial Pharmaceuticals is www.adialpharma.com.

Adial Pharmaceuticals is headquartered at 1180 Seminole Trail Suite 495, Charlottesville VA, 22901.

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at (434) 422-9800 or via email at [email protected]